Barrett’s Esophagus – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Barrett's Esophagus Market Outlook

Thelansis’s “Barrett's Esophagus Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barrett's Esophagus treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Barrett's Esophagus Overview

Barrett's esophagus is a condition in which columnar cells replace squamous cells in the esophageal mucosa. The condition is understood to be a complication of gastroesophageal reflux disease. Its significance stems from its proclivity to develop into esophageal cancer. The mucosa of the normal esophagus comprises squamous cells, which are similar to those found on the skin or in the mouth. The normal squamous mucosal surface is whitish-pink, in sharp contrast to the salmon pink to the red appearance of the gastric mucosa, which is composed of columnar cells. The squamocolumnar (SC) junction, also known as the "Z-line," is a demarcation line that represents the normal esophagogastric junction where the squamous mucosa of the esophagus and columnar mucosa of the stomach meet. Barrett's esophagus is distinguished by variable distal esophageal segments lined by columnar mucosa. According to recently published guidelines, a diagnosis of Barrett's esophagus should be reserved for patients with a specific type of columnar mucosa. On microscopic examination, this mucosa, known as "specialized columnar epithelium" or "distinctive-type Barrett's epithelium," contains a mixture of gastric mucin-containing cells and intestinal goblet cells. Most patients with extensive distal esophageal columnar mucosa have a mix of gastric-type mucosal cells and specialized columnar mucosa. The specialized columnar mucosa appears to be at risk for malignant degeneration.

• Barrett's esophagus develops in about 15 to 20% of patients with chronic gastroesophageal reflux or inflammation of the esophagus. It occurs more often in men than women, with a 3:1 ratio.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: